13.13
-0.6(-4.37%)
Currency In USD
| Previous Close | 13.73 |
| Open | 13.45 |
| Day High | 13.55 |
| Day Low | 12.88 |
| 52-Week High | 28.25 |
| 52-Week Low | 6.98 |
| Volume | 3.87M |
| Average Volume | 5.53M |
| Market Cap | 1.47B |
| PE | -3.73 |
| EPS | -3.52 |
| Moving Average 50 Days | 13.59 |
| Moving Average 200 Days | 13.29 |
| Change | -0.6 |
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
GlobeNewswire Inc.
Mar 03, 2026 12:30 PM GMT
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needsCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWI
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced tha
Intellia Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be p